Finance

Beta
Lists
524715:BOM
Sun Pharmaceutical Industries Ltd
₹1,779.35
-0.56%
(-10.10) 1D
Jun 4, 3:53:41 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524715...
Open
₹1,781.95
High
₹1,793.60
Low
₹1,769.00
Mkt. cap
4.27T
Avg. vol.
165.45K
Volume
158.05K
P/E ratio
38.52
52-wk high
₹1,917.15
52-wk low
₹1,547.25
EPS
₹46.20
Shares outstanding
0.00
No. of employees
43K
Open
₹1,781.95
High
₹1,793.60
Low
₹1,769.00
Mkt. cap
4.27T
Avg. vol.
165.45K
Volume
158.05K
P/E ratio
38.52
52-wk high
₹1,917.15
52-wk low
₹1,547.25
EPS
₹46.20
Shares outstanding
0.00
No. of employees
43K
News stories
From sources across the web
Profile
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
About Sun Pharmaceutical Industries Ltd
CEO-
Employees43K
Founded1983
HeadquartersGoregaon East, Mumbai, India
SectorPharmaceutical industry
Websitesunpharma.com
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
138.51B
144.78B
155.21B
146.12B
Cost of goods sold
28.15B
29.83B
29.45B
28.01B
Cost of revenue
28.15B
29.83B
29.45B
28.01B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
28.02B
27.65B
28.92B
29.60B
Operating expense
76.65B
81.28B
85.13B
90.59B
Total operating expenses
104.79B
111.11B
114.58B
118.60B
Operating income
33.72B
33.67B
40.62B
27.52B
Other non operating income
4.64B
4.70B
5.79B
3.73B
EBT including unusual items
31.63B
41.55B
42.07B
35.37B
EBT excluding unusual items
39.81B
41.55B
46.97B
35.37B
Income tax expense
8.70B
10.31B
8.26B
8.28B
Effective tax rate
27.51%
24.80%
19.63%
23.40%
Other operating expenses
41.62B
46.34B
48.89B
53.23B
Net income
22.79B
31.18B
33.69B
27.14B
Net profit margin
16.45%
21.54%
21.71%
18.57%
Earnings per share
11.98
13.00
15.48
11.30
Interest and investment income
-
-
-
-
Interest expense
-748.00M
-998.60M
-783.60M
-
Net interest expenses
-748.00M
-998.60M
-783.60M
-
Depreciation and amortization charges
7.01B
7.30B
7.32B
7.75B
EBITDA
39.63B
40.82B
46.53B
34.86B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer